Evidence map›Paper›PMID 39706898›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Editorial Commentary: Should "heterogeneous response" be considered as new category for assessing treatment response in patients with breast cancer?

Sofia C Vaz, David Groheux, Thiemo van Nijnatten, Lidija Antunovic, Fatima Cardoso, Felix Mottaghy, Maria Joao Cardoso, Christopher Riedl, Lioe-Fee de Geus-Oei, Gary A Ulaner

Abstract readEditorial
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Heterogeneous treatment response in metastatic breast cancer: discordance between FDG-PET and CT classification.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sofia C VazNuclear Medicine- Radiopharmacology, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.ORCID http://orcid.org/0000-0003-4229-9349
David GroheuxNuclear Medicine Department, Saint- Louis Hospital, Paris, France.ORCID http://orcid.org/0000-0002-9541-9175
Thiemo van NijnattenDepartment of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands.ORCID http://orcid.org/0000-0002-6431-3538
Lidija AntunovicDepartment of Nuclear Medicine, Ospedale San Raffaele, Milan, Italy.ORCID http://orcid.org/0000-0003-1832-1083
Fatima CardosoBreast Unit, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.ORCID http://orcid.org/0000-0002-6692-2249
Felix MottaghyDepartment of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands.ORCID http://orcid.org/0000-0002-7212-6521
Maria Joao CardosoBreast Unit, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.
Christopher RiedlImagingWest, Hawthorne, NY, USA.ORCID http://orcid.org/0000-0001-7913-8827
Lioe-Fee de Geus-OeiDepartment of Radiology, Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0003-1817-2743
Gary A UlanerMolecular Imaging and Therapy, Hoag Family Cancer Institute, Newport Beach, CA, USA. Gary.Ulaner@hoag.org.ORCID http://orcid.org/0000-0002-7953-0113

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.